Current state of screening for Down's syndrome

Annals of Clinical Biochemistry

Volumn 39, Issue 1, 2002, Pages 1-11

  Holding, Stephen ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRIOL; INHIBIN A; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

CALCULATION; DIAGNOSTIC ACCURACY; DISEASE MARKER; DOWN SYNDROME; FETUS CELL; FETUS RISK; FIRST TRIMESTER PREGNANCY; HEALTH CARE POLICY; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; MATERNAL AGE; MATERNAL BLOOD; NEWBORN; PATIENT MONITORING; PRENATAL SCREENING; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; TECHNOLOGY; TRISOMY 21; ULTRASOUND; UNITED KINGDOM;

BIOLOGICAL MARKERS; DOWN SYNDROME; FEMALE; FORECASTING; HUMANS; MASS SCREENING; MATERNAL AGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS;

EID: 0036154071     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563021901559     Document Type: Review

References (103)

1. Down's syndrome screening in the UK in 1998
2. Existence and quality of written antenatal screening policies in the United Kingdom: Postal survey
3. Observations on an ethnic classification of idiots
4. A population-based study on the causes of mild and severe mental retardation
5. Management of Down's syndrome
6. Down syndrome in Kuwait
7. Cytogenetic study of the heterochromatic polymorphisms in 100 subjects with Down syndrome and their parents
8. Study of Down syndrome in 238,942 consecutive births
9. Screening for Down's syndrome
10. A collaborative study of the segregation of inherited chromosome structural rearrangements in 1356 prenatal diagnoses
11. Risks of unbalanced progeny at amniocentesis to carriers of chromosome rearrangements: Data from United States and Canadian laboratories
12. Results of first year (1989) of a national register of Down's syndrome in England and Wales
13. Joint estimation of Down syndrome risk and ascertainment rates: A meta-analysis of nine published data sets
14. Down syndrome in the Negev region (1975-1981)
15. Congenital malformations. A report of a study of series of consecutive births in 24 centres
16. Down syndrome in India
17. Racial variations in the incidence of trisomy 21
18. Down syndrome and trisomy 18 in the Bedouins
19. Differences in maternal age-specific rates of Down syndrome between Jews of European origin and of North African or Asian origin
20. Report of National Institute of Child Health and Human Development Workshop on chorionic villus sampling and limb and other defects, October 20, 1992
21. Amniocentesis
22. Variation in biochemical screening for Down's syndrome in the United Kingdom
23. Estimating the spontaneous loss of Down syndrome foetuses between the times of chorionic villus sampling, amniocentesis and live birth
24. Foetal loss in Down syndrome pregnancies
25. Down syndrome foetal loss rate in early pregnancy
26. Down syndrome foetal loss rate in early pregnancy
27. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level
28. Maternal serum screening for Down's syndrome in early pregnancy
29. Nomograms to help inform women considering Down's syndrome screening
30. Frequency of births with potentially avoidable serious chromosomal anomalies in EEC countries, 1979-1982
31. Maternal serum screening
32. Down syndrome screening
33. The effect of Down's syndrome screening policy on the efficacy of amniocentesis in the second trimester of pregnancy
34. Appropriate biochemical parameters in first-trimester screening for Down syndrome
35. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters
36. Maternal serum screening for Down syndrome in the first trimester: Experience from Belarus
37. Antenatal screening for Down's syndrome
38. Maternal urine hyperglycosylated hCG in pregnancies with Down syndrome
39. Biochemical screening for Down's syndrome
40. Screening by test combination: A statistical overview
41. Evaluation of effect of analytical imprecision on maternal serum screening for Down's syndrome
42. Maternal serum hCG and foetal nuchal translucency thickness for the prediction of foetal trisomies in the first trimester of pregnancy
43. First trimester screening for aneuploidy: Serum biochemical markers
44. Effect of study design on the association between nuchal translucency measurement and Down syndrome
45. First-trimester nuchal translucency and maternal serum biochemical screening for Down's syndrome: A happy union?
46. First-trimester screening for aneuploidy: Research or standard of care?
47. Established markers in second trimester maternal serum
48. Maternal serum markers for foetal trisomy 21 screening
49. Down syndrome: Prenatal risk assessment and diagnosis
50. Reinventing the wheel
51. Randomised comparison of routine versus highly selective use of Doppler ultrasound in low risk pregnancies
52. Sequelae and support after termination of pregnancy for foetal malformation
53. Adjusting the risk for trisomy 21 on the basis of second-trimester ultrasonography
54. UK multicentre project on assessment of risk of trisomy 21 by maternal age and foetal nuchal-translucency thickness at 10-14 weeks of gestation
55. Biparietal diameter and crown-rump length in foetuses with Down's syndrome: Implications for antenatal serum screening for Down's syndrome
56. Estimating gestational age in utero
57. The effects of gestation dating on the calculation of patient-specific risks in Down's syndrome screening: Multivariate case
58. Estimations of gestational age and screening for Down's syndrome
59. Maternal serum screening for Down's syndrome: The effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight
60. Model-based screening by risk with application to Down's syndrome
61. The mathematical basis of multivariate risk screening: With special reference to screening for Down's syndrome associated pregnancy
62. Improving methods of screening for Down's syndrome
63. Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland
64. MOMs (multiples of the median) and DADs (discriminant aneuploidy detection): Improved specificity and cost-effectiveness of biochemical screening for aneuploidy with DADs
65. Are DADs (discriminant aneuploidy detection) as good as MOMs (multiples of the median)?
66. Effect of maternal age curve on the predicted detection rate in maternal serum screening for Down syndrome
67. Software for prenatal Down syndrome risk calculation: A comparative study of six software packages
68. Taking account of vaginal bleeding in screening for Down's syndrome
69. Maternal smoking and Down syndrome: The confounding effect of maternal age
70. Serum markers at 15-22 weeks of pregnancy
71. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities
72. Maternal weight differences do not explain ethnic differences in biochemical screening
73. Medians for second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol; differences between races or ethnic groups
74. Effect of allowing for ethnic group in prenatal screening for Down's syndrome
75. Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: Impact on Down syndrome screening
76. The influence of smoking on maternal serum PAPP-A and free beta hCG levels in the first trimester of pregnancy
77. The influence of smoking on maternal serum AFP and free beta hCG levels and the impact on screening for Down syndrome
78. Does smoking influence serum alpha-fetoprotein levels in mid-trimester pregnancies?
79. Alpha-fetoprotein, vaginal bleeding and pregnancy risk
80. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: Implications for screening for Down's syndrome
81. Multiple marker screening for Down syndrome in twin pregnancies
82. Down's syndrome screening in twins
83. Screening for trisomy 21 in twin pregnancies in the first trimester using free beta-hCG and PAPP-A, combined with foetal nuchal translucency thickness
84. Maternal serum screening for Down's syndrome taking account of the result in a previous pregnancy
85. Between-pregnancy biological variability of maternal serum alpha-fetoprotein and free beta hCG: Implications for Down syndrome screening in subsequent pregnancies
86. Maternal serum alpha-fetoprotein screening. II. Pitfalls in low-volume decentralized laboratory performance
87. Detection rates and false positive rates for Down's syndrome screening: How precisely can they be estimated and what factors influence their value?
88. 154 Fear for their babies after Down's test error
89. First trimester prenatal diagnosis: Earlier is not necessarily better
90. Hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen) immunoassay: A new basis for gestational Down syndrome screening
91. Foetal cells in the maternal circulation: Feasibility for prenatal diagnosis
92. Increased foetal DNA concentrations in the plasma of pregnant women carrying foetuses with trisomy 21
93. A prospective comparative study on fluorescence in situ hybridization (FISH) of uncultured amniocytes and standard karyotype analysis
94. Fluorescence in situ hybridization of chorionic interphase cells for prenatal screening of Down syndrome
95. Same day diagnosis of Down's syndrome and sex in single cells using multiplex fluorescent PCR